ArticleCanadian journal of anaesthesia = Journal canadien d'anesthesie2020
Sugammadex use in patients with end-stage renal disease: a historical cohort study.
Article in Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Efficacy and Safety of Sugammadex for the Reversal of Rocuronium-Induced Neuromuscular Blockade in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2021Pooled it
- [Muscle relaxation 2026-50 years of searching for the ideal relaxant].Die Anaesthesiologie · 2026Review
- Sugammadex in Perioperative Neuromuscular Management: Current Advances and Best Practices.Current pharmaceutical design · 2026Review
- In-depth exploration of sugammadex and novel neuromuscular blockade antagonists: a narrative review.Frontiers in pharmacology · 2026Review
- Sugammadex for Neuromuscular Blockade Reversal: A Narrative Review.Journal of clinical medicine · 2025Review
- A Comparative Study of Sugammadex and Neostigmine: A Bibliometric Analysis of the Past 15 Years.Drug design, development and therapy · 2025Article
- Sugammadex use in pediatric patients with stage IV-V chronic kidney disease in a quaternary referral hospital: a case series.BMC anesthesiology · 2024Article
- Residual Neuromuscular Block Remains a Safety Concern for Perioperative Healthcare Professionals: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Considerations regarding anesthesia for renal transplantation.Anesthesia and pain medicine · 2024Review
- Effect of glycopyrrolate on the postoperative urine output of patients following kidney transplantation: a retrospective observational study.The Journal of international medical research · 2023Observational
- Reply to the Commentary on "An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant".Anaesthesiology intensive therapy · 2023Article
- Sugammadex administration in patients with end-stage renal disease: a narrative review with recommendations.Anesthesia and pain medicine · 2023Review
- Optimizing Reversal of Neuromuscular Block in Older Adults: Sugammadex or Neostigmine.Drugs & aging · 2022Article
- Postoperative mortality in patients with end-stage renal disease according to the use of sugammadex: a single-center retrospective propensity score matched study.Anesthesia and pain medicine · 2022Article
- Anaesthetic Approach to Enhanced Recovery after Surgery for Kidney Transplantation: A Narrative Review.Journal of clinical medicine · 2022Review
- Choice of neuromuscular block reversal agent to reduce postoperative pulmonary complications.Anesthesia and pain medicine · 2022Review
- Impact on grafted kidney function of rocuronium-sugammadex vs cisatracurium-neostigmine strategy for neuromuscular block management. An Italian single-center, 2014-2017 retrospective cohort case-control study.Perioperative medicine (London, England) · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWhile sugammadex (SGX) is not approved for use in patients with end-stage renal disease (ESRD), its administration in this patient population has been reported. We designed the current study to review all instances of patients with ESRD receiving SGX and to describe their clinical outcomes.
methodsThis is a historical cohort study of 219 patients with chronic kidney disease stage 5 who received SGX in one of three hospital locations within the same academic health system. Data were collected between 7 March 2016 and 1 August 2019 and included demographics, notable events from the anesthesia records, and postoperative complications. The primary outcome included any complication possibly related to SGX such as hypersensitivity reactions, need for reintubation, hypoxemia, pneumonia, and residual neuromuscular blockade. Secondary outcomes included any other complication not included in the primary outcome and/or patient mortality within 30 days after the procedure.
resultsNo patient experienced a hypersensitivity reaction. Three patients required reintubation while two patients developed hypoxemia that did not require reintubation. One patient developed hospital-acquired pneumonia. Fifty (23%) patients developed other postoperative complications (different from our primary outcome) and nine patients (4%) died during the subsequent 30 postoperative days. None of the primary or secondary outcomes appeared to be related to SGX use.
conclusionsWe provide incremental evidence that SGX could be considered as an alternative neuromuscular blockade reversal agent in patients with ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.